At the end of the year, the wave of departures is being staged in the pharmaceutical circle, including executives of domestic pharmaceutical companies such as Chengdu Pioneer and Huiyu Pharmaceutical, as well as executives of multinational pharmaceutical companies such as Roche, behind the changes in the senior management of these pharmaceutical companies, the changes in the pharmaceutical market are still intensifying
.
Roche: Head of the pharmaceutical division left
Recently, multinational pharmaceutical company Roche announced that its head of pharmaceutical division, Bill Anderson, decided to leave, which indicates that the company plans to change its CEO early next year, but also a broader management reshuffle
.
Roche said in a statement that Bill Anderson, head of Roche Genentech's division, will step down at the end of the year to pursue other opportunities, while a successor will take office in March 2023
.
Anderson's position will be temporarily replaced
by Thomas Schinecker.
The latter will be promoted to Group CEO in March, succeeding Severin Schwan as
CEO.
It is understood that Bill Anderson has worked for Roche for 16 years, he served as senior vice president of immunology and ophthalmology business unit in Roche Genentech, then mainly responsible for the biological oncology business unit, and has been the CEO
of Roche's pharmaceutical business since 2019.
Smart Pharmaceutical: Independent director resigned
Wisdom Pharma announced on December 14 that the company's board of directors recently received a written resignation report from Mr.
Zhang Jiguo, an independent director of the company, and Mr
.
Zhang Jiguo applied to resign as an independent director, a member of the strategy committee of the board of directors and a member of the remuneration and assessment committee of the fifth board of directors of the company due to personal reasons.
After his resignation, Mr.
Zhang Jiguo will no longer hold any position
in the Company.
On the same day, the Company agreed to elect Mr.
Yang Ling as an independent director with the approval of the Company's general meeting of shareholders, and will also serve as a member of the Company's Strategy Committee and the Remuneration and Assessment Committee
.
Chengdu Pioneer: Core technical personnel leave
On December 13, Chengdu Pilot announced that Mr.
Wan Jinqiao, a senior manager and core technical personnel of the company, recently submitted a resignation application to the company due to personal reasons, and will no longer hold any position
in the company after his resignation.
According to the announcement, during his tenure, Mr.
Wan Jinqiao was mainly responsible for leading the R&D Chemistry Center, undertaking the design and synthesis of DNA-encoded compound library (DEL), chemical services (small molecule compounds and compound libraries), etc
.
As of the disclosure date of this announcement, the company has been granted 71 patents, of which Mr.
Wan Jinqiao participated in research during his tenure and has obtained 37 authorized invention patents
.
The company said that the departure of Mr.
Wan Jinqiao will not have a substantial impact
on the company's operating ability, research and development strength and core competitiveness.
As of the end of 2020 and the end of 2021, the number of R&D personnel of the company was 383 and 391, accounting for 83.
62% and 83.
01% of the total number of employees, respectively, and the number of R&D personnel remained stable
.
Before and after this change, there were 4 core technical personnel left in the company
.
Huiyu Pharmaceutical: Core technical personnel left
On December 15, Huiyu Pharmaceutical announced that Mr.
Teng Yumin, the company's core technical personnel, recently submitted an application for resignation to the company due to personal reasons, and has completed the relevant resignation procedures
.
Mr.
Teng Yumin will no longer hold any position
in the Company after his resignation.
According to the announcement, Mr.
Teng Yumin was mainly responsible for the research and development of the company's biological innovative drugs, the establishment of the biological research institute and the creation of the research and development platform during his tenure
.
At present, the handover of work has been completed, and his departure will not adversely
affect the R&D project and department operation management.
During his tenure with the Company, Mr.
Teng Yumin did not participate in the authorized or pending patent-related work
.
As of the end of 2020, the end of 2021 and June 30, 2022, the number of R&D personnel of the company was 393, 642 and 664, accounting for 39.
33%, 43.
37% and 43.
29% of the total number of employees, respectively, and the number of R&D personnel maintained stable growth
.
Katazai: Directors resigned
On December 15, Katazai announced that Mr
.
Chen Zhiyan resigned from the board of directors due to work adjustment.
According to the relevant regulations, the resignation of Mr.
Chen Zhiyan did not cause the Board of Directors of the Company to fall below the quorum and would not affect the normal operation and daily operation
of the Board of Directors of the Company.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
